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Abstract. Background/Aim: The aim of this study was to
examine the clinicopathological features of intraductal
papillary neoplasm of the bile duct (IPNB) and investigate
their relationships with intraductal papillary mucinous
neoplasm (IPMN). Patients and Methods: Our study included
104 patients who underwent resection of tumors that showed
papillary growth within the bile duct and pancreas. Results:
Comparisons were performed based on subtypes and
histological grades. The presence of various histological
grades was confirmed in both the IPNB group and the IPMN
group, and statistical significance was found in the between-
group comparisons of subtypes and histological grades. It was
shown that while all patients who underwent IPNB resection
did not match the classifications proposed by Nakanuma et al.,
they did reflect classification characteristics. Conclusion:
IPNB and IPMN have common clinical histological features.
Common features between IPNB subtype classifications were
also identified, which may provide novel diagnostics.
Intraductal papillary neoplasm of the bile duct (IPNB) is an
epithelial tumor that shows papilloma within a dilated bile duct
and was first reported by Chen et al. in 2001 (1). Histologically,
IPNB are well-differentiated papillary adenocarcinomas or
borderline lesions and have been reported to resemble
intraductal papillary mucinous neoplasm (IPMN) (2). IPMN is
an epithelial tumor that displays papilloma accompanied by
mucin hypersecretion. IPMN is sub-classified according to
macroscopic characteristics, tissue morphology, and mucoid-
trait expression. IMPN is reported to have different malignancy
levels, prognoses, recurrence rates, etc. (3). While there is
consensus regarding disease concept, diagnosis, and treatment
of IPMN, sufficient consensus does not exist for IPNB because
it is a relatively new disease concept. Conventionally, bile duct
and pancreatic diseases have been classified from separate
viewpoints. Although the bile duct and pancreas have
anatomical and embryological similarities, IPNB has been
considered to be a counterpart of IPMN, and this logic is
convincing. Nevertheless, IPNB does not occur as frequently as
IPMN, and many uncertainties remain. The purpose of the
present study was to clarify the clinicopathological features of
IPNB and elucidate their relationship with pancreatic IPMN.
Patients and Methods
During our study period, from 2003 through 2015, 104 patients at the
Kurume University Hospital received resections for papillary growth
tumors within the bile duct and pancreas. After fixing the excised
specimens in 10% neutral buffered formalin solution, sections of 5 mm
thickness were prepared, and hematoxylin–eosin (HE) staining was
performed. The stained sections were clinicopathologically investigated
using microscopy. The clinicopathological investigation was performed
in reference to the WHO Classification of Tumors of the Digestive
System, 4th edition (4-6). The IPNB sub-classifications were performed
according to the classifications reported by Fukumura et al. (7).
Immunohistochemistry. Immunocytochemistry was performed on 4-
μm-thick sections of formalin-fixed, paraffin embedded tissues. The
sections were mounted on glass slides and then incubated with anti-
mouse monoclonal antibody against human MUC-1 (clone Ma695,
IgG1, 1:100 dilution; Leica Biosystems Newcastle, Ltd., Newcastle,
UK), anti-mouse monoclonal antibody against human MUC-2
(clone Cep58, IgG1, 1:100 dilution; Leica Biosystems), anti-mouse
monoclonal antibody against human MUC-5AC (clone CLH2, IgG1
1:100 dilution; Leica Biosystems), or anti-mouse monoclonal
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antibody against human MUC-6 (clone CLH5, IgG1 1:100 dilution;
Leica Biosystems) on the same fully automated Bond-III system
(Leica Microsystems) using onboard heat-induced antigen retrieval
with epitope retrieval solution 2 for 20 min at 99˚C. Each slide was
incubated with the antibody for 30 min at room temperature. This
automated system uses a Refine polymer detection kit with
horseradish peroxidase-polymer as a secondary antibody and DAB,
and incubation with a secondary antibody was performed for 30 min
at room temperature (Figure 1).
All Immunohistochemical analyses were evaluated by two
experienced observers who were unaware of the patients’ conditions.
Statistical analysis. Clinicopathologic factors were compared
between the two groups, the IPNB and IPMN group, using the
Student’s t-test, chi-squared test, and Kruskal–Wallis test. Overall
survival (OS) curves were created for both groups using the
Kaplan–Meier method, and the log-rank test was used to examine
the survival curves. The significance level was set at p<0.05, and
JMP Pro 11.0.0 (SAS Institute Inc., Cary, NC, USA) was used for
the analysis.
Results
There were 28 cases in the IPNB group including
intracholecystic papillary neoplasm (ICPN) in the gallbladder
and 76 cases in the IPMN group. Of these patients, 24 with
IPNB and 74 with IPMN were suitable for histopathological
examination. The patients with IPNB ranged from 49 to 83
years (mean 68.2 years) in age, with a male:female ratio of
20:8. The patients with IPMN ranged in age from 51 to 82
years (mean 66.7 years), with a male:female ratio of 57:19. Of
the IPNB cases, 5 were intrahepatic and 23 were extrahepatic
(gallbladder 5 cases). The following IPNB surgical treatments
were performed: 13 cases received pancreatoduodenectomy
(PD), 5 cases hepatectomy, 4 cases hepatectomy with biliary
resection, and 5 cases cholecystectomy with liver bed
resection. The following surgical treatments were performed
for IPMN: 34 cases received PD, 25 cases distal
pancreatectomy (DP), and 9 cases total pancreatectomy (TP). 
With respect to mucin hypersecretion, patients with IPMN
(79%) exhibited predominantly higher levels of mucin than
patients with IPNB (36%). The IPNB sub-classification
breakdown was as follows: 7 cases of gastric type, 3 cases
of intestinal type, 13 cases of pancreatobiliary type, and 1
case of oncocytic type. The IPMN sub-classification
breakdown was as follows: 26 cases of gastric type, 35 cases
of intestinal type, 10 cases of pancreatobiliary type, and 3
cases of oncocytic type. No significant differences were
found in the sub-classification comparisons between the two
groups. The nodule size was 3.34±0.41 cm in patients with
IPNB and 2.50±0.23 cm in patients with IPMN, and this
difference was not statistically significant.
The breakdown of histological grade was as follows.
IPNB: no patients had low to intermediate-grade dysplasia,
13 patients had a high-grade dysplasia, and 11 patients had
IPNB-derived invasive carcinoma; IPMN: 22 patients had
low to intermediate-grade dysplasia, 16 patients had a high-
grade dysplasia, and 36 patients had IPMN-derived invasive
carcinoma. Significant differences were found in the
comparisons of each histological grade between groups.
Within the nodules of patients in the IPMN group, different
histological atypias were confirmed, while no such findings
were observed in the IPNB group (data not shown). With
respect to lymphatic invasion, neural invasion, and lymph
node metastasis, while significant differences were not
confirmed between the groups, the IPNB group displayed
significantly higher venous invasion (Table Ⅰ). Regarding
prognosis, while the IPNB group had 5-year overall survival
rate of 100%, the 5-year survival rate for the IPMN group
was 75%. However, this difference was not statistically
significant (Figure 2).
Nakanuma et al. proposed two sub-classifications based
on histopathological findings (8), and we investigated 28
cases of IPNB resection based on these sub-classifications.
While there were 5 cases of Type 1 IPNB, the majority of
which occurred in the intrahepatic bile duct, 4 of the 5 cases
had mucin hypersecretion, with the following subtypes: 2
case of pancreatobiliary type, 2 cases of gastric type, and 1
case of oncocytic type. Invasive cancer was found in 1 of the
5 cases. There were 23 cases of type 2 IPNB, all of which
were of extrahepatic origin. Mucin hypersecretion was
confirmed in 3 cases, and the cases were sub-classified as
follows: 13 cases of pancreatobiliary type, 4 cases of gastric
type, and 3 cases of intestinal type. Invasive cancer was
found in 10 of the 23 cases.
Discussion
Regarding age and sex comparisons, no significant
differences were found between the IPMN and IPNB
groups. Mucin hypersecretion was more frequently noted
in the IPMN group, and these findings were similar to those
reported by another study (7). There were, however, major
differences in mucus-trait type proportions between the two
groups, with the IPNB showing nearly half the amount of
MUC-1 expression relative to IPMN. Conversely, in the
IPMN group, frequent MUC-2 or MUC-5AC expression
was observed, thus demonstrating the differences in mucus-
expression types. These differences may be reflected in
sub-classification by types: while the IPNB group had
many pancreatobiliary types, the IPMN group had many
intestinal and gastric types. Gastric type IPMN had the
second-most sub-classification numbers. Since the
treatment plans have been established for gastric type
IPMN (9), which comprises the majority of branch duct
IPMN, the rate of resection may be reduced in the future.
If this indeed proves true, then changes in intergroup
proportions may present as well. While no significant
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differences were found between the two groups in nodule
size, a significant difference was found in the proportions
of histological atypias.
A variety of histological atypias were found in the IPMN
group. For IPNB, while high-grade dysplasia to invasive
IPNB types were found, no low to intermediate-grade
dysplasia was observed. There are two possible reasons for
this. First, while the IPMN group had relatively larger
numbers of adenoma, given this group’s larger numbers of
gastric and intestinal types, the IPNB group had conversely
more pancreatobiliary types (3), with relatively higher
malignancies. Secondly, a relatively higher number of
patients with type 2 IPNB (so-called papillary carcinoma or
cholangiocarcinoma) could have been included in the IPNB
group (8). To minimize this possibility, we based our
investigation on the classifications proposed by Nakanuma
et al. (8) for the 28 cases of IPNB resection. Type 1 IPNB
was found to be frequently present as intrahepatic, and
mucin hypersecretion was also often observed. There were
few invasive cases, and their morphology was extremely
similar to that of IPMN. Meanwhile, type 2 IPNB was often
found in the extrahepatic bile duct, rarely presenting mucin
hypersecretion, and often exhibiting invasion. Thus, the
morphology of type 2 IPNB does not resemble that of IPMN.
While not all of the resection cases that were investigated in
this study matched these profiles, their features were in fact
reflected (Table Ⅱ).
In our present study, both groups had favorable 5-year
survival rates. This finding is similar to that of previous studies,
especially in the survival rates of patients in the IPNB group
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Figure 1. Morphological types of IPMN (×200). (A) Pancreatobiliary type, (B) gastric type, (C) intestinal type, (D) oncocytic type.
(10). Since a clear consensus does not exist for IPNB diagnosis
and treatment, as is the case for IPMN, these issues must be
clarified in the future. Because of the poor prognosis of invasive
cancers (11, 12), IPNB should be resected in a stage when it still
remains only intraepithelial. While it is currently difficult to
obtain definitive presurgical findings, reports have indicated the
possible usefulness of 18F-fluolodeoxyglucose (18F-FDG)
examination (13, 14). In presurgical FDG-PET/CT exams, as
malignancy rates increase, SUVmax has been found to increase
in 18F-FDG tests, which indicates the possibility that this method
to be useful for determining malignancy. Further investigations
will establish clear-cut IPNB diagnosis and treatment strategies. 
In conclusion, IPNB presented clinical histological
features that are common to those of IPMN. The common
features of IPNB subtype classifications (8) may provide
novel diagnostic criteria.
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Table Ⅰ. Background of patients and tumors, and evaluation of tumors. 
                                                                                         IPMN                                                  IPNB (ICPN)                                               p-Value
                                                                                         (n=76)                                                       (n=28)
Age (range)                                                                 66.7 (51-82)                                              68.2 (49-83)                                                   
Gender (M/F)                                                                   57/19                                                          20/8                                                          
Location                                                                        Branch 27                                              Intrahepatic 5
                                                                                        Main 40                                      Extrahepatic 23 (ICPN 5)
                                                                                         Mix  9
Surgical treatment                                                            PD 34                                                        PD 13
                                                                                         DP  25                                                        HT 5
                                                                                           TP 9                                       HT (with biliary resection) 4
                                                                                                                                                            CT 5
Mucin hypersecretion                                                   60 (79%)                                                   10 (36%)                                                  <0.0001
Subtype                                                                                                                                                                                                               0.0004
Gastric                                                                                 26                                                               7                                                             
Intestinal                                                                              35                                                               3                                                             
Pancreatobiliary                                                                  10                                                              13                                                            
Oncocytic                                                                             3                                                                1                                                             
Tumor size (cm)                                                           2.50±0.23                                                  3.34±0.41                                                   0.085
Histological grade                                                                                                                                                                                            <0.0001
LID                                                                                      22                                                               0                                                             
HGD                                                                                    16                                                              13                                                            
Invasive carcinoma                                                             36                                                              11                                                            
Ly (–/+)                                                                              39/9                                                           15/6                                                        0.47
V (–/+)                                                                               43/4                                                           15/7                                                        0.028
Ne (–/+)                                                                             39/8                                                           19/3                                                        0.65
Nodal Stage pn (0/1)                                                         41/6                                                            8/3                                                         0.26
PD: Pancreatoduodenectomy; DP: distal pancreatectomy; TP: total pancreatectomy; HT: hepatectomy; CT: cholecystectomy with liver bed resection;
LID: low-to intermediate-grade dysplasia; HGD: high-grade dysplasia; Ly: lymphatic invasion; V: venous invasion; Ne: neural invasion.
Table Ⅱ. Pathological features of two types of biliary papillary
neoplasms.
                                                   Type1 IPNB (n=5)  Type2 IPNB (n=23)
Location                                         Intrahepatic 5          Extrahepatic 23
Mucin hypersecretion                            4/5                            3/23
Subtype                                       Pancreatobiliary 2   Pancreatobiliary 13
                                                           Gastric 2                   Gastric 4
                                                         Intestinal 0                Intestinal 3
                                                        Oncocytic 1              Oncocytic 0
Associated with invasive cancer             1/5                           10/23
IPNB: Intraductal papillary neoplasms of the bile duct.
All Authors approved the final version of the manuscript, and
agreed to be accountable for all aspects of the work in ensuring that
questions related to the accuracy or integrity of any part of the work
are appropriately investigated and resolved.
References
1 Chen TC, Nakanuma Y, Zen Y, Chen MF, Jan YY, Yeh TS, Chiu
CT, Kuo TT, Kamiya J, Oda K, Hamaguchi M, Ohno Y, Hsieh
LL and Nimura Y: Intraductal papillary neoplasia of the liver
associated with hepatolithiasis. Hepatology 34(4 Pt 1): 651-658,
2001. PMID: 11584359. DOI: 10.1053/jhep.2001.28199
2 Zen Y, Sasaki M, Fujii T, Chen TC, Chen MF, Yeh TS, Jan YY,
Huang SF, Nimura Y and Nakanuma Y: Different expression
patterns of mucin core proteins and cytokeratins during
intrahepatic cholangiocarcinogenesis from biliary intraepithelial
neoplasia and intraductal papillary neoplasm of the bile duct--
an immunohistochemical study of 110 cases of hepatolithiasis. J
Hepatol 44(2): 350-358, 2006. PMID: 16360234. DOI: 10.1016/
j.jhep.2005.09.025
3 Hisaka T, Horiuchi H, Uchida S, Ishikawa H, Kawahara R,
Kawashima Y, Akashi M, Mikagi K, Ishida Y, Okabe Y,
Nakayama M, Naito Y, Yano H, Taira T, Kawahara A, Kage M,
Kinoshita H and Shirozu K: Potential usefulness of mucin
immunohistochemical staining of preoperative pancreatic biopsy
or juice cytology specimens in the determination of treatment
strategies for intraductal papillary mucinous neoplasm. Oncol
Rep 30(5): 2035-2041, 2013. PMID: 24008495. DOI: 10.3892/
or.2013.2720
4 Nakanuma Y, Curado MP and Franceschi S: Intrahepatic
cholangiocarcinoma. In: WHO Classification of Tumours of the
Digestive System; World Health Organization of Tumours.
Bosman FT, Carneiro F, Hruban RH and Theise ND (eds.). 4th
edition. Lyon: IARC, pp. 217-224, 2010.
5 Albores- Saavedra J, Adsay NV and Crawford JM: Carcinoma of
the gallbladder and extrahepatic bile duct. In: WHO Classification
of Tumours of the Digestive System; World Health Organization
of Tumours. Bosman FT, Carneiro F, Hruban RH and Theise ND
(eds.). 4th edition. Lyon: IARC, pp. 266-273, 2010.
6 Adsay NV, Fukushima N and Furukawa T: Intraductal Neoplasm
of the pancreas. In: WHO Classification of Tumours of the
Digestive System; World Health Organization of Tumours.
Bosman FT, Carneiro F, Hruban RH and Theise ND (eds.). 4th
edition. Lyon: IARC, pp. 304-313, 2010.
7 Fukumura Y, Nakanuma Y, Kakuda Y, Takase M and Yao T:
Clinicopathological features of intraductal papillary neoplasms
of the bile duct: a comparison with intraductal papillary
mucinous neoplasm of the pancreas with reference to subtypes.
Virchows Arch 471(1): 65-76, 2017. PMID: 28550497. DOI:
10.1007/s00428-017-2144-9
8 Nakanuma Y, Jang KT, Fukushima N, Furukawa T, Hong SM,
Kim H, Lee KB, Zen Y, Jang JY and Kubota K: A statement by
the Japan-Korea expert pathologists for future clinicopathological
and molecular analyses toward consensus building of intraductal
papillary neoplasm of the bile duct through several opinions at the
present stage. J Hepatobiliary Pancreat Sci 25(3): 181-187, 2018.
PMID: 29272078. DOI: 10.1002/jhbp.532
9 Tanaka M, Fernández-Del Castillo C, Kamisawa T, Jang JY, Levy
P, Ohtsuka T, Salvia R, Shimizu Y, Tada M and Wolfgang CL:
Revisions of international consensus Fukuoka guidelines for the
management of IPMN of the pancreas. Pancreatology 17(5): 738-
753, 2017. PMID: 28735806. DOI: 10.1016/j.pan.2017.07.007
10 Nanashima A, Imamura N, Sumida Y, Hiyoshi M, Hamada T and
Nagayasu T: clinicopathological aspects and diagnostic problems
in patients with intraductal papillary neoplasm of the bile duct.
Anticancer Res 38(4): 2343-2352, 2018. PMID: 29599359. DOI:
10.21873/anticanres.12481
11 Onoe S, Shimoyama Y, Ebata T, Yokoyama Y, Igami T, Sugawara
G, Nakamura S and Nagino M: Prognostic delineation of papillary
cholangiocarcinoma based on the invasive proportion: a single-
institution study with 184 patients. Surgery 155(2): 280-291, 2014.
PMID: 24287144. DOI: 10.1016/j.surg. 2013.08.011
12 Furukawa T, Hatori T, Fujita I, Yamamoto M, Kobayashi M,
Ohike N, Morohoshi T, Egawa S, Unno M, Takao S, Osako M,
Yonezawa S, Mino-Kenudson M, Lauwers GY, Yamaguchi H,
Ban S and Shimizu M: Prognostic relevance of morphological
types of intraductal papillary mucinous neoplasms of the
pancreas. Gut 60(4): 509-516, 2011. PMID: 21193453. DOI:
10.1136/gut.2010.210567
13 Ikeno Y, Seo S, Yamamoto G, Nakamoto Y, Uemoto Y, Fuji H,
Yoshino K, Yoh T, Taura K and Uemoto S: Usefulness of
preoperative 18F-FDG-PET in detecting invasive intraductal
papillary neoplasm of the bile duct. Anticancer Res 38(6): 3677-
3682, 2018. PMID: 29848727. DOI: 10.21873/anticanres.12645
14 Takanami K, Hiraide T, Tsuda M, Nakamura Y, Kaneta T, Takase
K, Fukuda H and Takahashi S: Additional value of FDG PET/CT
to contrast-enhanced CT in the differentiation between benign
and malignant intraductal papillary mucinous neoplasms of the
pancreas with mural nodules. Ann Nucl Med 25(7): 501-510,
2011. PMID: 21537945. DOI: 10.1007/s12149-011-0494-y 
Received May 23, 2019
Revised June 26, 2019
Accepted June 27, 2019
Sato et al: Clinicopathological Study of Resection of Bile Duct Tumors
4573
Figure 2. Overall survival in IPNB group and IPMN group. The 5-year
survival rate of IPMN is75%, and of IPNB is 100%. Dotted line: IPNB
group; solid line: IPMN group.
